Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Cited by 118 Publications

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )
Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )

Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )
Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )

Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )
Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )
J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Anticancer Res, 2015, 35(12):6623-32

PubMed: 26637878 ( click the link to review the publication )

Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	M4PSWWtqdmG\|ZTDBd5NigQ>?		NUjm[\|VyOjRiaB?=		MVHJcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>?	MVeyOFY1OTFyMx?=
COLO205	NEPtfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3PxelczKGh?		NUnmN3pqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkCzOkDPxE1?	NF\iflAzPDZ2MUGwNy=>
U937	NWfLeIRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFnWNos4OiCq		MkDMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=>	MkTWNlQ3PDFzMEO=
MOLM13	M4rqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mlv3O\|IhcA>?		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX\|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszN	MoXpNlQ3PDFzMEO=
MOLM13	M{Sz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fQdlczKGh?		MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO	NYD3ZpRVOjR4NEGxNFM>
MDA-MB-435	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn\uNlQhcA>?		NWm2c45EUUN3ME2wMlE3KM7:TR?=	NHK3SngyPThyMUizNS=>
K562	Ml\2R5l1d3SxeHnjJGF{e2G7		MkXyPVYhcA>?	NEHBUmlFVVOR	NH7y[llKSzVyPUKg{txO	MnnsNlQ1OTd3Nk[=
DU145	NHXmWIhEgXSxdH;4bYMhSXO\|YYm=		NG\FcWU6PiCq	MV3EUXNQ	MmfuTWM2OD15LkWg{txO	MVKyOFQyPzV4Nh?=
MDA-MB-231	M{HBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\uNUDPxE1?	MU[yOEBp	M{\qZWROW09?	MYrD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS\|EheGijc3W=	M4f5NFI1PDF5NU[2
MCF7	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPHbZl3OSEQvF2=	M4fuOFI1KGh?	M2LPSWROW09?	M4noeWNmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=>	NIfCepkzPDRzN{W2Oi=>
MCF7	M1HX[mtqdmG\|ZTDBd5NigQ>?	NGHlTYQ2KM7:TR?=	MX6yOEBp	NVnaOVhsTE2VTx?=	MYXJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET\|Qw[3mlbHnuSFEh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhy	MkO2NlQ1OTd3Nk[=
MDA-MB-231	MkftT4lv[XOnIFHzd4F6	MWG1JO69VQ>?	MXKyOEBp	NFXwZYVFVVOR	MlL1TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=	NUntXVNnOjR2MUe1OlY>
MDA-MB-231	MV\GeY5kfGmxbjDBd5NigQ>?	M4\1SFEuOTBizszN	NGnjXlczPCCq	M{XuO2ROW09?	MUfkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V?	NGK4[3UzPDRzN{W2Oi=>
MCF7	NYfMfYZTTnWwY4Tpc44hSXO\|YYm=	NWfiVJNqOS1zMDFOwG0>	NYLpcYJ[OjRiaB?=	MlLWSG1UVw>?	M1XUfoRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZR?=	MV2yOFQyPzV4Nh?=
MDA-MB-231	NX:0UVFUTnWwY4Tpc44hSXO\|YYm=	NXfXNG9vOC53LUGg{txO	MnXBOFghcA>?	MkDCSG1UVw>?	MmDTbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U>	NH3DSnQzPDRzN{W2Oi=>
MCF7	NE[0S4JHfW6ldHnvckBCe3OjeR?=	M4H6S\|AvPS1zIN88US=>	MVK0PEBp	NFL3OppFVVOR	M3PKdohieyCwbzDD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm	NI\UZYUzPDRzN{W2Oi=>
697	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3PcIpKSzVyPUG0PE4{QCCwTR?=	M1rzVnNCVkeHUh?=
P12-ICHIKAWA	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTl4LkC0JI5O	MV7TRW5ITVJ?
NB69	NXq0WGNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\sUWlEPTB;MU[xMlghdk1?	NUi3V2huW0GQR1XS
EoL-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\IUmlEPTB;MUi3MlI3KG6P	NWTXb41kW0GQR1XS
BHT-101	Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTF7OD6yOUBvVQ>?	NUfycmJ5W0GQR1XS
SK-NEP-1	NYL5bVNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULhWmZDUUN3ME2yNlAvODJibl2=	MmjrV2FPT0WU
MHH-NB-11	NXXwZ3dvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzycJdOUUN3ME2yNlAvOTlibl2=	MWnTRW5ITVJ?
AsPC-1	NHPVTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELDSFlKSzVyPUK1Nk42OyCwTR?=	NFXLN2ZUSU6JRWK=
ES1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XufmlEPTB;MkW2MlI2KG6P	MXzTRW5ITVJ?
LAMA-84	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmj6TWM2OD1{NUiuNVkhdk1?	MmO3V2FPT0WU
MOLT-16	M4PVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[4XZNKSzVyPUK1PE41QSCwTR?=	MVnTRW5ITVJ?
ES7	M1PSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkj2TWM2OD1{N{OuNFkhdk1?	NIjMNXJUSU6JRWK=
KY821	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjFN4s{UUN3ME2zNVQvOSCwTR?=	MmfHV2FPT0WU
RT-112	NWHsbnNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTN{MT6wOUBvVQ>?	NVTjXGdCW0GQR1XS
HL-60	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnr5TWM2OD1\|NECuOlYhdk1?	MmfFV2FPT0WU
MOLT-4	NYPae2c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlS0TWM2OD1\|NEWuNVMhdk1?	MmjIV2FPT0WU
KARPAS-45	NEPHZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXLT4d1UUN3ME2zO\|YvOTZibl2=	NHrUc4hUSU6JRWK=
SK-N-AS	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LxXmlEPTB;M{i3Mlg{KG6P	M2jnVnNCVkeHUh?=
CTB-1	NFe3TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTRyNT6wNkBvVQ>?	MWrTRW5ITVJ?
NKM-1	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWH3clBpUUN3ME20NVEvQDlibl2=	NHP1bI1USU6JRWK=
HTC-C3	NGHS[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3W5fWlEPTB;NEOyMlk2KG6P	MWPTRW5ITVJ?
BE-13	NX;nZ3lyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHmzbmJKSzVyPUS0OE4zPyCwTR?=	NIrqO4NUSU6JRWK=
KOSC-2	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITWeGlKSzVyPUS2Ok46KG6P	NX\jendnW0GQR1XS
NB14	NHfybmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrUW5hKSzVyPUS4N{42QCCwTR?=	MV;TRW5ITVJ?
CAL-27	M4PFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmKwTWM2OD12OUSuOVkhdk1?	MoTvV2FPT0WU
H9	M{DGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzSTWM2OD12OUWuOFMhdk1?	MmHPV2FPT0WU
RS4-11	M3Kw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fKTmlEPTB;NUC0Mlc{KG6P	Ml\yV2FPT0WU
PA-1	MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoS5TWM2OD13MEmuPFYhdk1?	NInVdJhUSU6JRWK=
MV-4-11	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGL4cJBKSzVyPUWxN{45PSCwTR?=	NXPuSZZxW0GQR1XS
OS-RC-2	M2\kXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjKe5JKSzVyPUWyNU43OiCwTR?=	NG\aSIpUSU6JRWK=
RPMI-8226	NYT1WVR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTV{Nj64OkBvVQ>?	MUHTRW5ITVJ?
HGC-27	NGj3RpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jzd2lEPTB;NU[0Mlk6KG6P	MXLTRW5ITVJ?
CHP-212	M1e3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mle2TWM2OD13OUOuOVkhdk1?	NYf1b5FOW0GQR1XS
NB10	NHPLZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlv3TWM2OD13OUmuNVghdk1?	M1HIOHNCVkeHUh?=
HH	NITmeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTV7OT60N{BvVQ>?	MkXHV2FPT0WU
EW-16	M2PKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XUTWlEPTB;NkCzMlUzKG6P	MmnMV2FPT0WU
ES8	M3\Vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTZyNT6yNUBvVQ>?	NXzoT4ZOW0GQR1XS
HAL-01	NV6xO3IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHqwXIJKSzVyPU[wOU43PyCwTR?=	NXXrPJgyW0GQR1XS
A204	M2nrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fXW2lEPTB;NkOzMlkyKG6P	MW\TRW5ITVJ?
MHH-PREB-1	NEjiWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVv5dVdFUUN3ME22N\|YvQTlibl2=	NWHWcGozW0GQR1XS
EM-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTZ3MD62OEBvVQ>?	M3fMbHNCVkeHUh?=
BV-173	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXK0eGZOUUN3ME22OVIvPDhibl2=	MXnTRW5ITVJ?
ONS-76	NELyeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkG1TWM2OD14N{euPFIhdk1?	MXTTRW5ITVJ?
KM-H2	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTZ7NT61OEBvVQ>?	NUfGTJN1W0GQR1XS
D-263MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3TTWM2OD15MUeuNVIhdk1?	M2nRb3NCVkeHUh?=
ES3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTd{OD65N{BvVQ>?	MYnTRW5ITVJ?
VA-ES-BJ	NUjF[XQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHpcGRKSzVyPUezNk4zPyCwTR?=	NVPmTGdvW0GQR1XS
NBsusSR	MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUn6TGQxUUN3ME23OFIvQTlibl2=	MWPTRW5ITVJ?
NCI-H520	M1LXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\1TWM2OD15NE[uOVIhdk1?	NXL6[nVoW0GQR1XS
ES5	M1Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXoTWM2OD15NUKuPEBvVQ>?	NHTqRoVUSU6JRWK=
T-24	NYXVPVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LBSmlEPTB;N{e4MlcyKG6P	NVXDUHBWW0GQR1XS
SW962	MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRThyOD62N{BvVQ>?	MYTTRW5ITVJ?
EW-3	M3vlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRThyOD63OkBvVQ>?	NYf2cndRW0GQR1XS
RXF393	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;wTWM2OD16MUKuO\|khdk1?	MkLyV2FPT0WU
U251	M4HydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLNU5pKSzVyPUixN{45QCCwTR?=	Mm\OV2FPT0WU
CAMA-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLzcnZKSzVyPUizN{46PCCwTR?=	NIPKUnNUSU6JRWK=
JVM-3	M{\Mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlH0TWM2OD16NUGuO\|ghdk1?	NHzuT2xUSU6JRWK=
COLO-800	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1T0bGlEPTB;OEm3Mlc5KG6P	NXn6TZFHW0GQR1XS
OVCAR-5	NEK0bFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTlyMD6xJI5O	M2fqPXNCVkeHUh?=
LB1047-RCC	NWKxN3Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTl{Nz61OkBvVQ>?	NIHwS\|lUSU6JRWK=
SW954	NHXsbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXMTWM2OD17MkmuOFEhdk1?	NVnTUnNQW0GQR1XS
J-RT3-T3-5	M1fH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;sOGlEPTB;OUO2MlA3KG6P	MnzDV2FPT0WU
Mewo	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vn[WlEPTB;OUO2MlYhdk1?	NFTUfVRUSU6JRWK=
NCI-H1770	NUP3bYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTl2MD61OUBvVQ>?	M{TXU3NCVkeHUh?=
HO-1-N-1	Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2O4Z2lEPTB;OU[yMlgyKG6P	NWjSZVJLW0GQR1XS
HSC-3	MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17yXWlEPTB;OU[2MlQ5KG6P	NVvPVXVLW0GQR1XS
TYK-nu	NFPMbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTl7OD6yOUBvVQ>?	MYLTRW5ITVJ?
KYSE-150	M1u2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TDc2lEPTB;MT6wNFA4PiEQvF2=	NWTBV5R6W0GQR1XS
SN12C	NWrCTY4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHq[29KSzVyPUGuNFA5PzVizszN	M2PY[XNCVkeHUh?=
MOLT-13	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HH[mlEPTB;MT6wNVQzOSEQvF2=	Ml:3V2FPT0WU
TE-11	NF;XU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\KR2lEPTB;MT6wOFgyOiEQvF2=	NUG1RW9qW0GQR1XS
DB	NFrzV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3:3WWlEPTB;MT6wO\|I4OyEQvF2=	M3rTcHNCVkeHUh?=
CAL-39	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTFwMEe1NlIh\|ryP	MXfTRW5ITVJ?
A3-KAW	NX35bopQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTFwMEi0NFgh\|ryP	M3TRd3NCVkeHUh?=
CHP-134	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\MTYJKSzVyPUGuNVE5ODdizszN	M{P2XHNCVkeHUh?=
TGW	NGrUR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTFwMUKzPVUh\|ryP	MYDTRW5ITVJ?
QIMR-WIL	M4P1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LVXmlEPTB;MT6xN\|E{PCEQvF2=	MnfEV2FPT0WU
NCI-SNU-1	NWnhfWFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\CfmlEPTB;MT6xOlM2PCEQvF2=	MYjTRW5ITVJ?
CGTH-W-1	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfqSZEyUUN3ME2xMlE4OTh4IN88US=>	NIXVPWRUSU6JRWK=
MHH-ES-1	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TafGlEPTB;MT6xO\|k5PiEQvF2=	NEHCSY9USU6JRWK=
LB2241-RCC	NWLVZXFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TQWGlEPTB;MT6xPFYzKM7:TR?=	M{foW3NCVkeHUh?=
ML-2	M3jLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPMTWM2OD1zLkKwO\|M1KM7:TR?=	MVnTRW5ITVJ?
COR-L23	M1;XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7RVYRKSzVyPUGuNlI6OzNizszN	NGTReWRUSU6JRWK=
BFTC-905	Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDLe5NKSzVyPUGuNlQzPjdizszN	M134eXNCVkeHUh?=
Hs-578-T	NVvkOHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrMZ4dUUUN3ME2xMlI2QDF5IN88US=>	M1jOfHNCVkeHUh?=
KG-1	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTFwMk[2PFYh\|ryP	NIrlUmFUSU6JRWK=
HEL	NYHVV\|FoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXS4NWZZUUN3ME2xMlI6OzN6IN88US=>	MVjTRW5ITVJ?
A549	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrOTWM2OD1zLkK5N\|k6KM7:TR?=	M3OxSHNCVkeHUh?=
COLO-741	NWHsdphnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\xTWM2OD1zLkOyNFg6KM7:TR?=	MW\TRW5ITVJ?
PC-3	MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEO0ZmtKSzVyPUGuN\|UzOjFizszN	MoTKV2FPT0WU
HOS	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTFwM{WyPVYh\|ryP	NWrCUZJuW0GQR1XS
HT-1080	NXHNfGhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFwM{e1NVkh\|ryP	M2HEZXNCVkeHUh?=
TE-8	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLHZWxKSzVyPUGuOFE4PzRizszN	NH\DO4RUSU6JRWK=
BHY	MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\STZhIUUN3ME2xMlQ3QTJ\|IN88US=>	NHPJPFFUSU6JRWK=
BB65-RCC	NEHIR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLDTWM2OD1zLkWwOVI5KM7:TR?=	M4rudXNCVkeHUh?=
HN	NHHiPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[2bmlEPTB;MT61OFA4OSEQvF2=	MULTRW5ITVJ?
NCI-H441	NITxbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnZO\|VKSzVyPUGuOVQ6ODdizszN	NYWxcZBnW0GQR1XS
RPMI-8866	NFT3XlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfPeoozUUN3ME2xMlU5PTB5IN88US=>	NUjBOY5FW0GQR1XS
CAL-62	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTFwNkC4OlIh\|ryP	M4\PSXNCVkeHUh?=
MG-63	NIfzWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTFwNkG4NVMh\|ryP	NXLkUZJWW0GQR1XS
SK-LU-1	M1HzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1joNGlEPTB;MT62NlE2OiEQvF2=	NEDycZpUSU6JRWK=
BCPAP	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4n5c2lEPTB;MT62OlQ2PyEQvF2=	NXnqXZFzW0GQR1XS
22RV1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPjTWM2OD1zLk[3PFQ{KM7:TR?=	NVjWPXJSW0GQR1XS
T47D	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDkT3duUUN3ME2xMlY5ODZzIN88US=>	NEPYdW1USU6JRWK=
MSTO-211H	NHS2UWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4i2TmlEPTB;MT62PVYxOyEQvF2=	NEP1eYdUSU6JRWK=
DEL	NVXtNnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\LeY5KSzVyPUGuO\|AzPzNizszN	MmfLV2FPT0WU
H4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\GTWM2OD1zLkezNlEzKM7:TR?=	NH\lU5pUSU6JRWK=
CAL-51	NEfnSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELTfVBKSzVyPUGuO\|Q5PTVizszN	NEW5dGJUSU6JRWK=
ABC-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4f5dWlEPTB;MT63PFU5OiEQvF2=	M2XBfXNCVkeHUh?=
MZ2-MEL	NXfreVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jFV2lEPTB;MT63PVU1OiEQvF2=	M4LLd3NCVkeHUh?=
YKG-1	NWO4emJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnTfmNNUUN3ME2xMlgyODZzIN88US=>	M4rEW3NCVkeHUh?=
KM12	NFfFVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\FTWM2OD1zLkixOlAzKM7:TR?=	NUjlZ\|FDW0GQR1XS
L-363	NXXrcmtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\OV\|JRUUN3ME2xMlg4PDF{IN88US=>	M1TmSHNCVkeHUh?=
KU812	M{T1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPHNYpLUUN3ME2xMlg6Ojh{IN88US=>	MlrvV2FPT0WU
LOXIMVI	NWP1XYNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrlZVdIUUN3ME2xMlkyOjJ6IN88US=>	NVfFR3hPW0GQR1XS
G-401	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVi3N4lZUUN3ME2xMlkzPDJ6IN88US=>	NYrkXVZqW0GQR1XS
SW780	MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XRNGlEPTB;MT65OlI1PiEQvF2=	Mlf2V2FPT0WU
SW872	Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jHZ2lEPTB;MT65PFM{KM7:TR?=	NGjHcGRUSU6JRWK=
NB7	NX;VSGY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvQNW5mUUN3ME2xMlk6OzJ\|IN88US=>	MlrFV2FPT0WU
T98G	MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJwMEC2OlYh\|ryP	MVTTRW5ITVJ?
SW1710	NVvxXZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTJwME[5OFUh\|ryP	M2nLXnNCVkeHUh?=
NCI-H1573	MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHWdlZKSzVyPUKuNFczQThizszN	NWHmUVlLW0GQR1XS
KE-37	MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn65TWM2OD1{LkC4PVUyKM7:TR?=	NFXMcWhUSU6JRWK=
786-0	NWTWOnpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnOdFVKSzVyPUKuNVU1OzlizszN	NYXnemdGW0GQR1XS
SAS	NUT4ZpgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\G[3cxUUN3ME2yMlIxOzd2IN88US=>	MVXTRW5ITVJ?
CAL-54	NF7XTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTJwMkC0NVMh\|ryP	MUPTRW5ITVJ?
SF268	M2\qb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLrd\|RuUUN3ME2yMlI{OTJ{IN88US=>	MX3TRW5ITVJ?
SW620	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HLUWlEPTB;Mj6yOlE3QSEQvF2=	NEfxcVBUSU6JRWK=
MN-60	NH3SNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nwdWlEPTB;Mj6zNVA3KM7:TR?=	M3\vTnNCVkeHUh?=
EFO-27	NYrOOWNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIeycIpKSzVyPUKuN\|IxPThizszN	Mom5V2FPT0WU
NCI-H747	NHntOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXrTWM2OD1{LkOyNVk6KM7:TR?=	MXLTRW5ITVJ?
HCC2218	M1HucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTJwM{WzO\|Qh\|ryP	M4\0d3NCVkeHUh?=
MIA-PaCa-2	MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DQVGlEPTB;Mj6zOlQ{PyEQvF2=	M{iw[nNCVkeHUh?=
SJSA-1	NYfYS3BtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHT4VYxKSzVyPUKuN\|c4QTZizszN	NEWycVBUSU6JRWK=
RKO	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrCcGJKSzVyPUKuN\|g1QTZizszN	M{WwN3NCVkeHUh?=
NB6	M1z3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PvOGlEPTB;Mj60NFM4PCEQvF2=	NETLbmVUSU6JRWK=
ES4	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXT2OJZOUUN3ME2yMlQ2PDJ{IN88US=>	NH[xTIRUSU6JRWK=
EGI-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrrV3lrUUN3ME2yMlQ3QDh\|IN88US=>	NEXFcJNUSU6JRWK=
CTV-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTJwNUK3O\|Mh\|ryP	NVLiWodsW0GQR1XS
NCI-H1355	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTJwNUW5OVEh\|ryP	NHvke5pUSU6JRWK=
GT3TKB	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJwNUmxPVkh\|ryP	NF;FN3lUSU6JRWK=
SK-HEP-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHKTWM2OD1{LkW5NlY3KM7:TR?=	NV3xdXdPW0GQR1XS
GAMG	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHu4fHpKSzVyPUKuOVk{QTRizszN	NGHlOohUSU6JRWK=
SK-MES-1	M{LZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYT0NoVbUUN3ME2yMlYyQDB\|IN88US=>	NGKzb\|lUSU6JRWK=
RO82-W-1	M4r0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\jZWdKSzVyPUKuOlIxPTdizszN	NVnleo53W0GQR1XS
ECC10	M{jodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTJwN{CyNFYh\|ryP	NHT5b3hUSU6JRWK=
MCF7	NHz2UZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJwN{G0OlQh\|ryP	MmW1V2FPT0WU
D-283MED	Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPmeIlKSzVyPUKuO\|I1OyEQvF2=	MlXlV2FPT0WU
RPMI-7951	NFT0WXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\BTWM2OD1{Lke1Olk1KM7:TR?=	M{\aRXNCVkeHUh?=
Ramos-2G6-4C10	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIO0ZXVKSzVyPUKuO\|cxQTlizszN	MkX3V2FPT0WU
KGN	MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rIZWlEPTB;Mj64NVg5PCEQvF2=	MVjTRW5ITVJ?
NUGC-3	NY[1XpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXJTWM2OD1{LkiyOVA2KM7:TR?=	Mlq1V2FPT0WU
NCI-H292	NIPvTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIq4O\|VKSzVyPUKuPFUxPTNizszN	MkLXV2FPT0WU
Becker	NYnXcJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfM[\|RyUUN3ME2yMlk2QDN{IN88US=>	M4OyZnNCVkeHUh?=
NCI-H1299	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoT0TWM2OD1\|LkC1NlY{KM7:TR?=	NEjId41USU6JRWK=
ETK-1	M1X3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjzfXRuUUN3ME2zMlA2PDNizszN	MkDYV2FPT0WU
TK10	NFGz[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7TbHpnUUN3ME2zMlIxOTZ3IN88US=>	NYDiPYJtW0GQR1XS
VMRC-RCZ	M4XTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlS0TWM2OD1\|LkO2OFg5KM7:TR?=	NYDsb2VmW0GQR1XS
YH-13	NIG3UnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTJfFlGUUN3ME2zMlQ1ODd7IN88US=>	MnOzV2FPT0WU
DU-145	M3TUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1L0SGlEPTB;Mz60OlI3QSEQvF2=	NXrZb4lrW0GQR1XS
SW1088	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPt[HFKSzVyPUOuOFc1PyEQvF2=	MX\TRW5ITVJ?
HOP-92	M{H0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorTTWM2OD1\|LkWwN\|QzKM7:TR?=	MljzV2FPT0WU
KP-N-YS	M3vHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LlNGlEPTB;Mz62NlE{QSEQvF2=	NWK1fpFpW0GQR1XS
NCI-H460	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF65bWVKSzVyPUOuOlY4OyEQvF2=	NEnrN2dUSU6JRWK=
U-2-OS	Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jFO2lEPTB;Mz63NlU{PSEQvF2=	NGfVS3hUSU6JRWK=
A101D	Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnaNG52UUN3ME2zMlc3QTN4IN88US=>	NITXfFRUSU6JRWK=
MDA-MB-231	NYrpVnY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPlT5JVUUN3ME2zMlgyQTVzIN88US=>	M2jGU3NCVkeHUh?=
IST-MES1	M3e4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XKS2lEPTB;Mz64N\|Ih\|ryP	NVrFW2FIW0GQR1XS
COR-L105	MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHFTWM2OD12LkCxPEDPxE1?	MWHTRW5ITVJ?
NCI-H1437	M2PpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTRwMEKzNFIh\|ryP	NYjyT4ZGW0GQR1XS
CAL-85-1	M2TZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnGwTWM2OD12LkCyOFYyKM7:TR?=	NEnsc3dUSU6JRWK=
MZ1-PC	M3PJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPFPIVZUUN3ME20MlE5PTV4IN88US=>	NHTtfFdUSU6JRWK=
VM-CUB-1	NH7mV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHPXpBrUUN3ME20MlMyOjh2IN88US=>	MYrTRW5ITVJ?
CHL-1	NXLv[HlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\UdGpKSzVyPUSuN\|IyPjlizszN	NHXGfIZUSU6JRWK=
MDA-MB-361	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTSTWM2OD12LkOzNVU{KM7:TR?=	NEGxb4dUSU6JRWK=
NCI-H661	NH:3bGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nreGlEPTB;ND61NFA6OiEQvF2=	MlKwV2FPT0WU
EW-11	M{DJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTRwNUKyN\|Eh\|ryP	MoTqV2FPT0WU
BEN	NGLLSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1n2WGlEPTB;ND61NlgyPSEQvF2=	MkLwV2FPT0WU
BFTC-909	M4LzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjGTWM2OD12LkW2Nlc2KM7:TR?=	M4fnR3NCVkeHUh?=
NCI-H2087	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELTXHRKSzVyPUSuOVgyPjRizszN	MVnTRW5ITVJ?
RVH-421	NFrIVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLGTWM2OD12Lk[2Olkh\|ryP	NX\jXIJlW0GQR1XS
P30-OHK	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLjW25KSzVyPUSuOlgxODhizszN	NYHzOVBqW0GQR1XS
NCI-H28	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{e3WGlEPTB;ND64NVY3OSEQvF2=	M2LvPXNCVkeHUh?=
ES6	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkH3TWM2OD12LkizNFE3KM7:TR?=	NGe3Z5dUSU6JRWK=
769-P	NEjjUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPWepBKSzVyPUSuPFU6OjZizszN	MYjTRW5ITVJ?
OE33	NVi3NYpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3W0e2lEPTB;ND64PFE3OSEQvF2=	NHPrNJpUSU6JRWK=
SW982	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\nW2RKSzVyPUSuPVUxPjFizszN	M1vvdnNCVkeHUh?=
A388	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnH3TWM2OD13LkCyPVg{KM7:TR?=	NVPpe2pFW0GQR1XS
TI-73	NFzQOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjtVHVyUUN3ME21MlA3OTl2IN88US=>	MXnTRW5ITVJ?
HCT-116	NGrncnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTVwMEm4PFkh\|ryP	M2PsdnNCVkeHUh?=
HuP-T3	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTVwMUi3NFkh\|ryP	MmfSV2FPT0WU
G-402	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFru[oZKSzVyPUWuNVk1OTZizszN	MXfTRW5ITVJ?
NCI-H1792	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEKzdIlKSzVyPUWuNlQ3OjJizszN	MYHTRW5ITVJ?
NCI-H209	MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4r4WGlEPTB;NT6yOVk1OiEQvF2=	NHnqeJhUSU6JRWK=
NCI-H1650	NG\ESYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTVwM{C2N\|Qh\|ryP	MXvTRW5ITVJ?
LCLC-97TM1	M1r5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3iyS2lEPTB;NT6zNVgxQCEQvF2=	MWTTRW5ITVJ?
S-117	M37MOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXtdoZKSzVyPUWuN\|Y6PzZizszN	NFq5SlRUSU6JRWK=
GI-ME-N	NYHFSpB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDIO\|BbUUN3ME21MlM6PjhzIN88US=>	NXfScXROW0GQR1XS
NCI-H2122	NEDXOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nVTWlEPTB;NT60PVM6PyEQvF2=	NH7VU4tUSU6JRWK=
NCI-H1793	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TpTGlEPTB;NT62O\|U6OyEQvF2=	MknRV2FPT0WU
C2BBe1	M1XzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTVwN{CwPFgh\|ryP	NUnifpV5W0GQR1XS
TE-12	MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzTW2JKSzVyPUWuPFA2PTZizszN	M3;zPHNCVkeHUh?=
LCLC-103H	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPCTWM2OD13LkmxO{DPxE1?	NFewXlNUSU6JRWK=
A673	NXrxOm81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmS3TWM2OD13LkmxPVMzKM7:TR?=	MnHQV2FPT0WU
BB30-HNC	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTVwOUizOkDPxE1?	MXjTRW5ITVJ?
SF295	NWH2NHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1O0N2lEPTB;Nj6wNFQzOiEQvF2=	NIPncI1USU6JRWK=
KU-19-19	M{H3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEeyRZhKSzVyPU[uNFE4OzFizszN	MoD0V2FPT0WU
CFPAC-1	MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkeyTWM2OD14LkC0OFQ{KM7:TR?=	MlfpV2FPT0WU
LoVo	NWfONZpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGO4NZFKSzVyPU[uNFUxPjNizszN	MkXLV2FPT0WU
8505C	MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\W[mlEPTB;Nj6wO\|U4OyEQvF2=	MlLIV2FPT0WU
GMS-10	M37rVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPiO4tKSzVyPU[uNVUxODJizszN	Ml;1V2FPT0WU
Ca9-22	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\sTWM2OD14LkG2O\|Eh\|ryP	MoDTV2FPT0WU
DOK	NYDBfXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLNTWM2OD14LkKyNFczKM7:TR?=	M3vjdnNCVkeHUh?=
FADU	Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrLR2I6UUN3ME22MlI3ODN7IN88US=>	M4HZRnNCVkeHUh?=
BxPC-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPUbmRKSzVyPU[uNlc{OiEQvF2=	M{S0dHNCVkeHUh?=
CAL-33	NHLtfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\qVmlEPTB;Nj6yPVIxOSEQvF2=	MknmV2FPT0WU
SHP-77	M1H0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nMOmlEPTB;Nj6zNVUyOiEQvF2=	MVvTRW5ITVJ?
LXF-289	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTZwM{O0OVUh\|ryP	MofFV2FPT0WU
GB-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPpVIVRUUN3ME22MlM5OiEQvF2=	NX\YUm92W0GQR1XS
KS-1	Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fP[mlEPTB;Nj6zPFQ1PyEQvF2=	Mm\0V2FPT0WU
D-502MG	MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlq0TWM2OD14LkSyN\|c3KM7:TR?=	MYHTRW5ITVJ?
LAN-6	M2TROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnXblIyUUN3ME22MlUyODJ\|IN88US=>	MVLTRW5ITVJ?
H-EMC-SS	NHS0VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTZwNU[xOFch\|ryP	NGTUW5NUSU6JRWK=
LC-2-ad	NF7VVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLCc41xUUN3ME22MlYxODd4IN88US=>	M1z4fXNCVkeHUh?=
NCI-H1693	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTZwNkKyNVUh\|ryP	Ml3XV2FPT0WU
SK-N-FI	NYrkdHc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rDe2lEPTB;Nj63OVA1PCEQvF2=	NXPQe3drW0GQR1XS
D-423MG	NUWxUmpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvlTnIzUUN3ME22Mlc3OTF5IN88US=>	MnO3V2FPT0WU
KNS-42	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfQc4pKSzVyPU[uO\|gyQTdizszN	MlLvV2FPT0WU
GCT	NIDqTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTZwOUO4JO69VQ>?	NUjHfohtW0GQR1XS
DSH1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mke1TWM2OD15LkC2N\|Mh\|ryP	NYDITFRuW0GQR1XS
D-247MG	M2\5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnyT\|ZKSzVyPUeuNFc5QDFizszN	M3yySnNCVkeHUh?=
NCI-SNU-5	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWX0cWxvUUN3ME23MlE5OzdzIN88US=>	MVzTRW5ITVJ?
TE-6	NET6NVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHuTZRKSzVyPUeuNlA3ODFizszN	MUfTRW5ITVJ?
NOMO-1	M1f1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmCxTWM2OD15LkKyNVI4KM7:TR?=	M3rPW3NCVkeHUh?=
NB17	NUTkRYxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;jTWM2OD15LkOwN\|A6KM7:TR?=	M4LMSnNCVkeHUh?=
EW-22	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTdwM{SzOFgh\|ryP	NYL3bFB5W0GQR1XS
EW-13	NX7mbm5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojwTWM2OD15LkO1NVYzKM7:TR?=	MXXTRW5ITVJ?
DOHH-2	NE\FSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTdwNESwNkDPxE1?	M3i3Z3NCVkeHUh?=
TGBC1TKB	NVPqRW9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHNUJlKSzVyPUeuOFk5QTlizszN	MoLuV2FPT0WU
GR-ST	NIfKNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnTW4FKSzVyPUeuOVI2QTRizszN	M3:5fnNCVkeHUh?=
KYSE-520	M3Gy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPyTWM2OD15LkW1OVE2KM7:TR?=	M3rRe3NCVkeHUh?=
CAPAN-1	MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTdwNUm1NUDPxE1?	Ml3BV2FPT0WU
HCE-4	M4TOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\6TWM2OD15Lk[yNlc6KM7:TR?=	NWTlR5ZkW0GQR1XS
MLMA	M3vKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TzXWlEPTB;Nz62Nlk2PyEQvF2=	M3mzOHNCVkeHUh?=
HT-144	NHzVZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojFTWM2OD15Lk[1N\|Y5KM7:TR?=	NFnIPVFUSU6JRWK=
KYSE-180	MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTdwN{GxOlkh\|ryP	MUHTRW5ITVJ?
TE-5	NWDpcZZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU[2[VYzUUN3ME23Mlk2QTdzIN88US=>	NUj3UJV[W0GQR1XS
IGROV-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTdwOUi1OVEh\|ryP	M{K2cnNCVkeHUh?=
NCI-H1581	NWn5fpdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7penZKSzVyPUiuNFEzKM7:TR?=	M2j6e3NCVkeHUh?=
SW1990	NETWS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRThwMES2OVkh\|ryP	MlXCV2FPT0WU
EFM-19	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nRfmlEPTB;OD6wPFU1PSEQvF2=	M1;YU3NCVkeHUh?=
OGR-1	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1K1eGlEPTB;OD60N\|AzOyEQvF2=	NYC2TXBYW0GQR1XS
U-118-MG	NXnu[VF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TVPGlEPTB;OD60N\|Q3OyEQvF2=	NEjDdG1USU6JRWK=
SK-OV-3	M1;EUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRThwNE[3OlUh\|ryP	Mm\wV2FPT0WU
KNS-62	M2L3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjQ[Y9EUUN3ME24MlUyPzZzIN88US=>	MYnTRW5ITVJ?
GOTO	M13QcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojvTWM2OD16LkW3OlM2KM7:TR?=	NFztUmlUSU6JRWK=
8305C	M1TIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRThwN{C0PFQh\|ryP	MVHTRW5ITVJ?
RPMI-2650	NHvIPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrPT5p7UUN3ME24MlcyQTV3IN88US=>	MYfTRW5ITVJ?
NEC8	Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HEcGlEPTB;OD63OFMxPyEQvF2=	M1XtOXNCVkeHUh?=
KYSE-450	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPTeZJYUUN3ME24Mlg3PTR6IN88US=>	MWXTRW5ITVJ?
RMG-I	NG\Wc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFizO\|BKSzVyPUmuNVQxPThizszN	MXHTRW5ITVJ?
CAKI-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjsW2pKSzVyPUmuN\|E6PzlizszN	NXvFSZZyW0GQR1XS
KYSE-510	NUfHcXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NES3NIhKSzVyPUmuN\|U4PzhizszN	M3SxdHNCVkeHUh?=
A4-Fuk	MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPuUYNKSzVyPUmuN\|Y4ODFizszN	NYLiZ2dGW0GQR1XS
AN3-CA	M2DyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\oSWlEPTB;OT60OVQ1PCEQvF2=	NHzWXIZUSU6JRWK=
SK-N-DZ	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmO5TWM2OD17LkeyPFQ6KM7:TR?=	MWnTRW5ITVJ?
HSC-2	NV\ZdZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrmc\|IyUUN3ME25Mlc3PjJ7IN88US=>	MW\TRW5ITVJ?
EW-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPwW2VKSzVyPUmuO\|k{PjlizszN	MoXjV2FPT0WU
D-566MG	M{nNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTlwOEO2OlQh\|ryP	NUnCUWNYW0GQR1XS
COLO-792	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUGxO4hqUUN3ME25Mlk5PzR4IN88US=>	NEHPRVVUSU6JRWK=
TE-10	NGPnc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{ewRWlEPTB;MUCuNFM6PiEQvF2=	NX\HeXBOW0GQR1XS
NCI-H650	M{TZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXDWlg1UUN3ME2xNE41Ojh4IN88US=>	M13VcHNCVkeHUh?=
U-266	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnYUpVpUUN3ME2xNE41PTVizszN	NXLEVVdGW0GQR1XS
Detroit562	NEf3V49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTFzLkC1NVUh\|ryP	NUn6T\|ViW0GQR1XS
NH-12	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTFzLkG0OFYh\|ryP	NVnmW2VSW0GQR1XS
CO-314	NGDOV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHGx[4ZKSzVyPUGxMlI5PDJizszN	MnXZV2FPT0WU
IST-MEL1	M4fKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTxblBHUUN3ME2xNU42OzJ\|IN88US=>	MnnZV2FPT0WU
KNS-81-FD	MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFzLkW1Nlch\|ryP	NInDNYNUSU6JRWK=
SW1463	NFflU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rTeGlEPTB;MUGuOVk5QSEQvF2=	NWK2XJNCW0GQR1XS
NCI-H23	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fVVGlEPTB;MUGuOlU2OiEQvF2=	MYXTRW5ITVJ?
SK-MEL-2	NGT2N2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLiTWM2OD1zMT63NVk4KM7:TR?=	M{W3fnNCVkeHUh?=
NB13	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWj6[JZxUUN3ME2xNk4yPDl3IN88US=>	NYqzV2JjW0GQR1XS
Daoy	NH3CS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfUWXQ5UUN3ME2xNk4zQDV4IN88US=>	MWrTRW5ITVJ?
NCI-H1623	MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTF{LkO4NFEh\|ryP	M4mx[HNCVkeHUh?=
NMC-G1	M4qwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTF{LkexO{DPxE1?	M1PL[3NCVkeHUh?=
DK-MG	NXLxPXZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUT4WWpqUUN3ME2xNk46PDh{IN88US=>	NFztWJBUSU6JRWK=
TCCSUP	NF\ZZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrOTWM2OD1zMz6xNlg1KM7:TR?=	MWrTRW5ITVJ?
SCC-15	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{C2d2lEPTB;MUOuNlY2OSEQvF2=	NEW0SnpUSU6JRWK=
NOS-1	NV;6TZljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\PcGlEPTB;MUOuNlg6OyEQvF2=	Mn7vV2FPT0WU
RH-1	NV[we5h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\BfohNUUN3ME2xN{4{ODN5IN88US=>	NWe0SWVSW0GQR1XS
SK-MEL-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLjTWM2OD1zMz6zO\|I5KM7:TR?=	Mn73V2FPT0WU
NB5	NX3OUHI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3UTWM2OD1zMz60NFY4KM7:TR?=	NIHKe4lUSU6JRWK=
SNU-387	NV\INGVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPSTWM2OD1zMz61NFczKM7:TR?=	NXLGNpNPW0GQR1XS
CAL-120	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTF\|Lk[3NVgh\|ryP	NXTtdlRzW0GQR1XS
Mo-T	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHv3fmdKSzVyPUGzMlcxPyEQvF2=	NVvmXopmW0GQR1XS
LNCaP-Clone-FGC	M3nQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HCb2lEPTB;MUOuO\|k6OiEQvF2=	MXLTRW5ITVJ?
CAN	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2i3VWlEPTB;MUSuNFI5QCEQvF2=	NYXB[5lyW0GQR1XS
SK-MEL-30	M1Ly[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF2LkC2N{DPxE1?	MYrTRW5ITVJ?
COLO-678	NVHlXHJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTF2LkC4NlIh\|ryP	M1ztNHNCVkeHUh?=
SCC-9	NEnhN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\vWGlEPTB;MUSuNVAzOSEQvF2=	MknuV2FPT0WU
KINGS-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fENGlEPTB;MUSuNVQxOiEQvF2=	MofUV2FPT0WU
SL-513	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXu2NVZYUUN3ME2xOE4yQDdizszN	NITpV3hUSU6JRWK=
HLE	M3PlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTPTWM2OD1zND6zPFUzKM7:TR?=	M37TO3NCVkeHUh?=
SW1573	NIPjTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLSTWM2OD1zND60OFM2KM7:TR?=	NV3ZVm1CW0GQR1XS
KYSE-140	MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDxTXhFUUN3ME2xOE43OzJ5IN88US=>	NVvmN5V5W0GQR1XS
SK-PN-DW	NU\ibJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTF2LkiwNFEh\|ryP	MkfLV2FPT0WU
A253	NYO2Wo86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3se5FKSzVyPUG1MlA3OjVizszN	Ml7tV2FPT0WU
CAL-12T	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4POO2lEPTB;MUWuOFY3OiEQvF2=	NEmxcIlUSU6JRWK=
COLO-679	MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlz6TWM2OD1zNT63Olg{KM7:TR?=	NX3RSmVbW0GQR1XS
UACC-257	Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHH1PFhKSzVyPUG2MlEzODFizszN	NX;HSYNwW0GQR1XS
U-87-MG	M{fvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rjNmlEPTB;MU[uN\|UzOyEQvF2=	M1jUWnNCVkeHUh?=
HCC1806	NXHIWVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnVUWNvUUN3ME2xOk44ODdzIN88US=>	M1jHcXNCVkeHUh?=
NCI-H2170	MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvpTWM2OD1zNz6yOFQ5KM7:TR?=	M{nhZ3NCVkeHUh?=
AGS	NY\kWXBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTFRnhKSzVyPUG3MlM5ODhizszN	NInvbpFUSU6JRWK=
MEL-HO	NIHNUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfBTWM2OD1zNz63OVA{KM7:TR?=	NH:yfnNUSU6JRWK=
SW48	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Tld2lEPTB;MUeuO\|cyPiEQvF2=	MkHpV2FPT0WU
HuP-T4	NXLocYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVW2fmd{UUN3ME2xPE4xOjB4IN88US=>	NGntb4VUSU6JRWK=
NCI-H720	M4jGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGS4UZVKSzVyPUG4MlE1ODJizszN	MUHTRW5ITVJ?
RCC10RGB	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLLTWM2OD1zOD6xOlk4KM7:TR?=	MUTTRW5ITVJ?
HD-MY-Z	Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTF6LkKyOVQh\|ryP	MUnTRW5ITVJ?
A427	NWq3cnF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULIRnZVUUN3ME2xPE42ODl2IN88US=>	M2LHZ3NCVkeHUh?=
HCC2998	NWDu[GJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDOcXVxUUN3ME2xPE43ODVzIN88US=>	NET4eZBUSU6JRWK=
EPLC-272H	M{C2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXOVpdKSzVyPUG5MlA1OzRizszN	NGrqS\|NUSU6JRWK=
C32	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDzTWM2OD1zOT6wOFUh\|ryP	M1fU[3NCVkeHUh?=
UMC-11	NV7P[4l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3X0ZmlEPTB;MUmuNlEzOyEQvF2=	NF7qXXdUSU6JRWK=
CaR-1	M3\5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;yTWM2OD1zOT62PFA1KM7:TR?=	MnvJV2FPT0WU
KYSE-410	NFPyfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXizW2xtUUN3ME2xPU46OTN7IN88US=>	MkPaV2FPT0WU
HuCCT1	M{HWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTJyLk[yPVQh\|ryP	MV;TRW5ITVJ?
LB996-RCC	NWf1SnVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\5WYc1UUN3ME2yNE44OTZ6IN88US=>	Ml3xV2FPT0WU
KYSE-70	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3NTWM2OD1{MD64NFU6KM7:TR?=	MUPTRW5ITVJ?
CAL-72	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MornTWM2OD1{MD65NVUh\|ryP	NGHVXpFUSU6JRWK=
Capan-2	NInUd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTKTWM2OD1{MT6wOFE{KM7:TR?=	NHLZUGdUSU6JRWK=
PANC-08-13	NYH4XXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmryTWM2OD1{MT6yOVE2KM7:TR?=	NHy1dZJUSU6JRWK=
SBC-1	NILnR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrK[JFKSzVyPUKxMlMxQDFizszN	MnLNV2FPT0WU
MFM-223	NEDiUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jpc2lEPTB;MkGuN\|M1OiEQvF2=	MXfTRW5ITVJ?
BB49-HNC	MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJzLkW3NVYh\|ryP	MVjTRW5ITVJ?
SH-4	M173Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\TWWlEPTB;MkGuOlYyQCEQvF2=	MYTTRW5ITVJ?
HuO9	NXTtfohbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXNTWM2OD1{MT65PFI2KM7:TR?=	MmDJV2FPT0WU
AM-38	MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\TbYw{UUN3ME2yNk4xPDh3IN88US=>	MXnTRW5ITVJ?
A431	M1Ps[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDNTWM2OD1{Mz6yNVE6KM7:TR?=	MXnTRW5ITVJ?
YAPC	Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTJ\|LkK2OVEh\|ryP	NFLWcVNUSU6JRWK=
LU-139	M3W3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{L3c2lEPTB;MkOuOFgxQSEQvF2=	MojUV2FPT0WU
HEC-1	NUP1NFRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEWy[FJKSzVyPUKzMlQ6OzdizszN	M3fZSHNCVkeHUh?=
SCC-25	NWXyd4dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTJ2LkOwNFYh\|ryP	MUTTRW5ITVJ?
HT-29	NGi5S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEW4NIJKSzVyPUK0MlM5OjNizszN	MYHTRW5ITVJ?
PC-14	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX[wfZRtUUN3ME2yOE43PTdzIN88US=>	MoriV2FPT0WU
Calu-6	MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\YOmlEPTB;MkWuOVA4OSEQvF2=	MVTTRW5ITVJ?
SJRH30	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYT5bHI4UUN3ME2yOU43PDl4IN88US=>	NGPZcWFUSU6JRWK=
ChaGo-K-1	NXjnOGhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYG5R3dSUUN3ME2yOk4yPjJ7IN88US=>	MVjTRW5ITVJ?
IA-LM	Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\nTWM2OD1{Nj6zOlQ2KM7:TR?=	MnLKV2FPT0WU
GP5d	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFf2fWFKSzVyPUK2MlQ1QTFizszN	NGPteXlUSU6JRWK=
NCI-H2291	MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUX3bFdRUUN3ME2yOk43PTRzIN88US=>	NIH6b\|lUSU6JRWK=
BALL-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPHTWM2OD1{Nj65N\|k4KM7:TR?=	NWm0VVhSW0GQR1XS
HCC1954	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1niemlEPTB;Mk[uPVgxQCEQvF2=	MUHTRW5ITVJ?
NCI-H2452	M4\QdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXmTWM2OD1{Nz60NVY{KM7:TR?=	Mlf1V2FPT0WU
LU-99A	M3PidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVe0VmFTUUN3ME2yO{42PTh{IN88US=>	MYPTRW5ITVJ?
NTERA-S-cl-D1	M{SxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzSXZJKSzVyPUK3MlczQTlizszN	NILuNpdUSU6JRWK=
PANC-10-05	MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4roVmlEPTB;MkeuO\|c4PSEQvF2=	NEHzNo1USU6JRWK=
NCI-H2405	NYLCRWlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{X3T2lEPTB;MkeuPVM5PyEQvF2=	NIPoVWxUSU6JRWK=
MDA-MB-415	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLtTWM2OD1{OD60NVM4KM7:TR?=	MnHKV2FPT0WU
NCI-H2342	MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLjOm5tUUN3ME2yPE42OjhzIN88US=>	M3roUHNCVkeHUh?=
TGBC24TKB	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fQfWlEPTB;MkiuO\|EyPyEQvF2=	M{TWV3NCVkeHUh?=
LU-134-A	MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTJ6LkmyOlEh\|ryP	M2XYUnNCVkeHUh?=
SCC-4	NGPiWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XqO2lEPTB;M{GuNFQ6PCEQvF2=	M4LMcHNCVkeHUh?=
Saos-2	NXjVTWxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3pe4J1UUN3ME2zNU46OzB4IN88US=>	MXvTRW5ITVJ?
RERF-LC-MS	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTNZ\|JKSzVyPUOyMlgzOzFizszN	NW\ZcJh[W0GQR1XS
M14	NWHOWHNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTN{Lkm3OlQh\|ryP	MmXxV2FPT0WU
HPAF-II	NHPV[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4GyPGlEPTB;M{OuOVAyOSEQvF2=	NYDNXVREW0GQR1XS
NCI-H1755	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fOWmlEPTB;M{SuN\|MxPSEQvF2=	Mnn2V2FPT0WU
D-392MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXTTWM2OD1\|NT64Olc1KM7:TR?=	MXXTRW5ITVJ?
A704	MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDETWM2OD1\|Nj6wOFI4KM7:TR?=	NH;DNVFUSU6JRWK=
CP50-MEL-B	NEDHS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn64TWM2OD1\|Nj6xPVEyKM7:TR?=	MlzUV2FPT0WU
EW-18	NH3LNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTN4LkS1NkDPxE1?	NUm0Uop3W0GQR1XS
WM-115	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPmUpVKSzVyPUO2MlgxQTlizszN	NWKzbGlDW0GQR1XS
LU-65	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzJTWM2OD1\|Nz6xOFE4KM7:TR?=	MUjTRW5ITVJ?
NCI-H1563	NWqxbFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mof0TWM2OD1\|Nz6yOFg1KM7:TR?=	NFizTFBUSU6JRWK=
DBTRG-05MG	M{\NZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTN6LkC2PVEh\|ryP	NXnDS2VyW0GQR1XS
NCI-H630	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPR[HFKSzVyPUO4MlQ4OTRizszN	M1\INXNCVkeHUh?=
NCI-H1155	M1\tWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTN7LkK0NkDPxE1?	M3i2XHNCVkeHUh?=
OVACR-3	NHXxV\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEW3W\|hKSzVyPUO5MlkyQTVizszN	NYP1[lU2W0GQR1XS
OAW-42	NEjZWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXCTWM2OD12MD60NlU5KM7:TR?=	MXjTRW5ITVJ?
JVM-2	NYXvZVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXv5OZF{UUN3ME20NU4zPDF3IN88US=>	MVrTRW5ITVJ?
C3A	M13TcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrtNVZKSzVyPUSxMlM1PDdizszN	MkC0V2FPT0WU
HT55	NGPZWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\qPWlEPTB;NEKuNlg1OSEQvF2=	M321S3NCVkeHUh?=
OVCAR-4	NX\kXVJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1j5UmlEPTB;NEKuNlk4PCEQvF2=	NF;RfGZUSU6JRWK=
MEG-01	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYOxdFhFUUN3ME20Nk41PjF4IN88US=>	M1ewOHNCVkeHUh?=
NCI-H82	M{LiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHl[49KSzVyPUSzMlk5QTJizszN	NVTLWYU6W0GQR1XS
JEG-3	NGToSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXucIQ{UUN3ME20OE46PDdizszN	M{\oUnNCVkeHUh?=
BPH-1	MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnqSXZEUUN3ME20Ok4{QTl6IN88US=>	M37nXnNCVkeHUh?=
MPP-89	NH[3RppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzjOpJKSzVyPUS3MlI5QThizszN	NWnmfmM2W0GQR1XS
ALL-PO	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfrfFQzUUN3ME20O{41OTh6IN88US=>	NVKyUZE2W0GQR1XS
HT	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHWTWM2OD12Nz60PVIh\|ryP	MWXTRW5ITVJ?
NCI-H2347	NIrZXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M373NmlEPTB;NEiuNFcyPSEQvF2=	NUHVW5Q2W0GQR1XS
A2780	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nBd2lEPTB;NEmuOFIzQCEQvF2=	Mme1V2FPT0WU
KARPAS-299	M33NPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTR7LkWxNVkh\|ryP	M{TMWXNCVkeHUh?=
NCI-H1651	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDzTWM2OD12OT64PFIyKM7:TR?=	M{HpTHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0) Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03870919	Not yet recruiting	Drug: Palbociclib\|Other: locoregional treatment	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	October 15 2019	Not Applicable
NCT03900884	Not yet recruiting	Drug: Venetoclax\|Drug: Palbociclib\|Drug: Letrozole	Breast Neoplasm Female	Peter MacCallum Cancer Centre Australia	September 2019	Phase 1
NCT03844997	Recruiting	Drug: Palcociclib\|Drug: CPX-351	Acute Myeloid Leukemia\|AML	Aziz Nazha\|Case Comprehensive Cancer Center	May 31 2019	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl

Cited by 118 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl

Cited by 118 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)